Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital.
Background: Infection with Hepatitis C virus (HCV) is a major cause of chronic liver disease, WHO estimated that about 170 million people are infected with Hepatitic C virus, Silymarin (Legalon) have been recently shown to be effective in treatment of Hepatitic C virus infection. Objectives: The eff...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
College of Medicine University of Baghdad
2017-04-01
|
Series: | مجلة كلية الطب |
Subjects: | |
Online Access: | http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/150 |
_version_ | 1827363954384437248 |
---|---|
author | Khalid A. Al-Khazraji |
author_facet | Khalid A. Al-Khazraji |
author_sort | Khalid A. Al-Khazraji |
collection | DOAJ |
description | Background: Infection with Hepatitis C virus (HCV) is a major cause of chronic liver disease, WHO estimated that about 170 million people are infected with Hepatitic C virus, Silymarin (Legalon) have been recently shown to be effective in treatment of Hepatitic C virus infection.
Objectives: The effectiveness of Legalon (Silymarin) on viral load in patients with Hepatitic C virus infection.
Patients and methods: A prospective case – control study included 400 patients with Hepatitis C virus infection. 200 patients (group A) were treated with (peg-interferon, ribavirin, silymarin) the other 200 patients (group B) were treated with (peg-interferon, ribavirin) . only G1 & G4 genotypes were included , viral load were assessed initially and after 3 months in patients with positive viral load.
Results: Viral load follow in group A, Hepatitis C Viral load was reported in 150 cases giving a response rate of 75% while in the 200 cases of group B the response was reported in 110 giving an overall response rate 55% , this indicate that cases in group A had a significant higher response rate than those in group B.
Conclusion: Patients taking Silymarin (420 mg/day) for 3 months showed a decrease in viral load, effectiveness of silymarin was more in Genotype 1 than in the Genotype 4, the response was better in low viral load patients ( less than 600000 IU/ml). |
first_indexed | 2024-03-08T07:58:55Z |
format | Article |
id | doaj.art-a68bcebad0d545c99c5e1f6d6a95b8e8 |
institution | Directory Open Access Journal |
issn | 0041-9419 2410-8057 |
language | English |
last_indexed | 2024-03-08T07:58:55Z |
publishDate | 2017-04-01 |
publisher | College of Medicine University of Baghdad |
record_format | Article |
series | مجلة كلية الطب |
spelling | doaj.art-a68bcebad0d545c99c5e1f6d6a95b8e82024-02-02T12:59:12ZengCollege of Medicine University of Baghdadمجلة كلية الطب0041-94192410-80572017-04-0159110.32007/med.1936/jfacmedbagdad.v59i1.4Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital.Khalid A. Al-Khazraji0Dept. Of medicine, university of BaghdadBackground: Infection with Hepatitis C virus (HCV) is a major cause of chronic liver disease, WHO estimated that about 170 million people are infected with Hepatitic C virus, Silymarin (Legalon) have been recently shown to be effective in treatment of Hepatitic C virus infection. Objectives: The effectiveness of Legalon (Silymarin) on viral load in patients with Hepatitic C virus infection. Patients and methods: A prospective case – control study included 400 patients with Hepatitis C virus infection. 200 patients (group A) were treated with (peg-interferon, ribavirin, silymarin) the other 200 patients (group B) were treated with (peg-interferon, ribavirin) . only G1 & G4 genotypes were included , viral load were assessed initially and after 3 months in patients with positive viral load. Results: Viral load follow in group A, Hepatitis C Viral load was reported in 150 cases giving a response rate of 75% while in the 200 cases of group B the response was reported in 110 giving an overall response rate 55% , this indicate that cases in group A had a significant higher response rate than those in group B. Conclusion: Patients taking Silymarin (420 mg/day) for 3 months showed a decrease in viral load, effectiveness of silymarin was more in Genotype 1 than in the Genotype 4, the response was better in low viral load patients ( less than 600000 IU/ml).http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/150Hepatitis C, Treatment, Silymarin effects on treatment. |
spellingShingle | Khalid A. Al-Khazraji Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital. مجلة كلية الطب Hepatitis C, Treatment, Silymarin effects on treatment. |
title | Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital. |
title_full | Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital. |
title_fullStr | Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital. |
title_full_unstemmed | Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital. |
title_short | Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital. |
title_sort | comparison study between the treatment of hepatitis c virus with peg interferon ribavirin silymarin and peg interferon ribavirin in baghdad teaching hospital |
topic | Hepatitis C, Treatment, Silymarin effects on treatment. |
url | http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/150 |
work_keys_str_mv | AT khalidaalkhazraji comparisonstudybetweenthetreatmentofhepatitiscviruswithpeginterferonribavirinsilymarinandpeginterferonribavirininbaghdadteachinghospital |